Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.

Vaccines explored for cancer therapy have been based generally on injectable vector systems used to control foreign infectious pathogens, to which the immune system evolved to respond naturally. However, these vectors may not be effective at presenting tumor-associated antigens (TAA) to the immune system in a manner that is sufficient to engender antitumor responses. We addressed this issue with a novel orally administered Salmonella-based vector that exploits a type III secretion system to deliver selected TAA in the cytosol of professional antigen-presenting cells in situ. A systematic comparison of candidate genes from the Salmonella Pathogenicity Island 2 (SPI2) locus was conducted in the vaccine design, using model antigens and a codon-optimized form of the human TAA survivin (coSVN), an oncoprotein that is overexpressed in most human cancers. In a screen of 20 SPI2 promoter:effector combinations, a PsifB::sseJ combination exhibited maximal potency for antigen translocation into the APC cytosol, presentation to CD8 T cells, and murine immunogenicity. In the CT26 mouse model of colon carcinoma, therapeutic vaccination with a lead PsifB::sseJ-coSVN construct (p8032) produced CXCR3-dependent infiltration of tumors by CD8 T cells, reversed the CD8:Treg ratio at the tumor site, and triggered potent antitumor activity. Vaccine immunogenicity and antitumor potency were enhanced by coadministration of the natural killer T-cell ligand 7DW8-5, which heightened the production of IL12 and IFNγ. Furthermore, combined treatment with p8032 and 7DW8-5 resulted in complete tumor regression in A20 lymphoma-bearing mice, where protective memory was demonstrated. Taken together, our results demonstrate how antigen delivery using an oral Salmonella vector can provide an effective platform for the development of cancer vaccines.

[1]  Z. Berneman,et al.  Clinical use of dendritic cells for cancer therapy. , 2014, The Lancet. Oncology.

[2]  G. Freeman,et al.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.

[3]  T. Kaisho,et al.  Invariant NKT Cells Induce Plasmacytoid Dendritic Cell (DC) Cross-Talk with Conventional DCs for Efficient Memory CD8+ T Cell Induction , 2013, The Journal of Immunology.

[4]  E. Manuel,et al.  A road less traveled paved by IDO silencing , 2013, Oncoimmunology.

[5]  B. Blazar,et al.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. , 2012, Cancer research.

[6]  K. Odunsi,et al.  CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. , 2012, Cancer research.

[7]  M. Hensel,et al.  Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens , 2012, Infection and Immunity.

[8]  S. Vasan,et al.  Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. , 2011, Clinical immunology.

[9]  L. Metelitsa.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. , 2011, Clinical immunology.

[10]  M. Hensel,et al.  Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. , 2011, Cancer research.

[11]  C. Klebanoff,et al.  Therapeutic cancer vaccines: are we there yet? , 2011, Immunological reviews.

[12]  M. Hensel,et al.  Efficacy of Intracellular Activated Promoters for Generation of Salmonella-Based Vaccines , 2010, Infection and Immunity.

[13]  D. Ho,et al.  Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant , 2010, Proceedings of the National Academy of Sciences.

[14]  M. Levine.  Typhoid vaccines ready for implementation. , 2009, The New England journal of medicine.

[15]  M. Hensel,et al.  Novel cancer vaccine based on genes of Salmonella pathogenicity island 2 , 2009, International journal of cancer.

[16]  G. Besra,et al.  Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity , 2009, Proceedings of the National Academy of Sciences.

[17]  S. H. van der Burg,et al.  Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients? , 2008, Clinical Cancer Research.

[18]  R. Steinman,et al.  Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells , 2007, The Journal of experimental medicine.

[19]  B. Shalmon,et al.  CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. , 2007, Cancer research.

[20]  R. Steinman,et al.  Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin1 , 2006, The Journal of Immunology.

[21]  M. Hensel,et al.  Manipulating cellular transport and immune responses: dynamic interactions between intracellular Salmonella enterica and its host cells , 2006, Cellular microbiology.

[22]  N. Lemoine,et al.  Bacterial gene therapy strategies , 2006, The Journal of pathology.

[23]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Marlovits,et al.  Structural Insights into the Assembly of the Type III Secretion Needle Complex , 2004, Science.

[25]  J. Pawelek,et al.  Bacteria as tumour-targeting vectors. , 2003, The Lancet. Oncology.

[26]  Youjin Lee,et al.  Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells , 2003, The Journal of experimental medicine.

[27]  S. Gillies,et al.  Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. , 2003, Blood.

[28]  W. Goebel,et al.  Recombinant attenuated bacteria for the delivery of subunit vaccines. , 2001, Vaccine.

[29]  M. Hensel,et al.  Salmonella Pathogenicity Island 2 , 2000, Molecular microbiology.

[30]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[31]  Hong Zhang,et al.  Mob-1, a Ras target gene, is overexpressed in colorectal cancer , 1997, Oncogene.

[32]  J. Shea,et al.  Simultaneous identification of bacterial virulence genes by negative selection. , 1995, Science.

[33]  Andrew D. Luster,et al.  γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins , 1985, Nature.

[34]  V. Cerundolo,et al.  Harnessing invariant NKT cells in vaccination strategies , 2009, Nature Reviews Immunology.

[35]  M. Smyth,et al.  CD1-restricted T cells and tumor immunity. , 2007, Current topics in microbiology and immunology.

[36]  Mitchell Kronenberg,et al.  Toward an understanding of NKT cell biology: progress and paradoxes. , 2005, Annual review of immunology.